XTX Topco Ltd acquired a new position in Inogen, Inc. (NASDAQ:INGN – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 21,859 shares of the medical technology company’s stock, valued at approximately $178,000. XTX Topco Ltd owned about 0.09% of Inogen at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. Meeder Asset Management Inc. purchased a new stake in shares of Inogen in the second quarter worth approximately $30,000. PNC Financial Services Group Inc. grew its position in Inogen by 2,918.3% in the 4th quarter. PNC Financial Services Group Inc. now owns 7,908 shares of the medical technology company’s stock valued at $43,000 after acquiring an additional 7,646 shares during the last quarter. CWM LLC increased its stake in Inogen by 2,185.9% in the second quarter. CWM LLC now owns 6,629 shares of the medical technology company’s stock worth $54,000 after purchasing an additional 6,339 shares during the period. Susquehanna Fundamental Investments LLC bought a new stake in shares of Inogen during the first quarter worth $81,000. Finally, Pitcairn Co. purchased a new stake in shares of Inogen during the first quarter valued at $86,000. Hedge funds and other institutional investors own 89.94% of the company’s stock.
Inogen Trading Up 0.1 %
Shares of Inogen stock opened at $9.70 on Tuesday. Inogen, Inc. has a 12 month low of $4.13 and a 12 month high of $13.33. The stock’s fifty day moving average price is $11.03 and its 200-day moving average price is $8.97. The firm has a market cap of $228.70 million, a P/E ratio of -2.34 and a beta of 1.05.
Analyst Ratings Changes
Several research analysts recently commented on INGN shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Inogen in a research note on Wednesday, August 7th. StockNews.com upgraded shares of Inogen from a “sell” rating to a “hold” rating in a research note on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $7.00.
Check Out Our Latest Stock Report on INGN
About Inogen
Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Read More
- Five stocks we like better than Inogen
- Why Are Stock Sectors Important to Successful Investing?
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- 3 Small Caps With Big Return Potential
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Want to see what other hedge funds are holding INGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inogen, Inc. (NASDAQ:INGN – Free Report).
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.